Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBT Margin (2016 - 2025)

Northwest Biotherapeutics' EBT Margin history spans 16 years, with the latest figure at 4550.89% for Q4 2025.

  • Quarterly results put EBT Margin at 4550.89% for Q4 2025, down 753915.0% from a year ago — trailing twelve months through Dec 2025 was 1587.59% (up 24743.0% YoY), and the annual figure for FY2025 was 4404.86%, up 165722.0%.
  • EBT Margin for Q4 2025 was 4550.89% at Northwest Biotherapeutics, up from 8470.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 12090.04% in Q4 2024 to a low of 12675.57% in Q2 2025.
  • The 5-year median for EBT Margin is 3816.5% (2023), against an average of 3984.67%.
  • The sharpest move saw EBT Margin skyrocketed 42657356bps in 2021, then plummeted -892165bps in 2025.
  • Year by year, EBT Margin stood at 3329.43% in 2021, then increased by 2bps to 3249.41% in 2022, then decreased by -13bps to 3681.8% in 2023, then surged by 428bps to 12090.04% in 2024, then plummeted by -62bps to 4550.89% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 4550.89%, 8470.5%, and 12675.57% for Q4 2025, Q3 2025, and Q2 2025 respectively.